Please log in to view this page
Username
Password
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
